Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


CrowdStrike punches above its weight in $612m IPO
Alphabet, Telstra and RackSpace-backed endpoint cybersecurity technology producer CrowdStrike will float above a range it had already increased.
Sansan sets price for $360m IPO
CyberAgent, GMO, Japan Post, Nikkei, Nippon Life, Recruit and Salesforce-backed Sansan priced its shares at the top of its range today and will raise $360m including the over-allotment option.
Whispir winds toward public listing
The Telstra and Telkom-backed enterprise messaging software provider priced its shares at the foot of the IPO's range but is in line to raise $32.5m when it floats next month.
Ideaya realises $50m IPO
Ideaya priced its shares below their range to raise $50m, providing exits for Alphabet, WuXi AppTec, Celgene, Roche and Novartis.
Bicycle Therapeutics rides into public markets
GlaxoSmithKline, Novartis and Astellas are among the investors to have celebrated an exit after cancer therapy developer Bicycle secured $60.7m in its initial public offering.
Fastly hits public markets with $180m
The O'Reilly Media, Deutsche Telekom and Swisscom-backed content delivery software provider floated at the top of its range and popped on its first day of trading.
Applied Therapeutics administers $40m IPO
Alexandria Real Estate Equities-backed Applied Therapeutics has gone public despite having to drastically cut its expectations for the offering.
Cortexyme caps IPO at just over $86m
Cortexyme has added $11.3m to its initial public offering, after the Pfizer, Takeda and Alphabet-based Alzheimer’s therapy developer raised $75m last week.

Other News

Sonim summons public listing
Motorola and JVC Kenwood-backed rugged electronics producer has floated below its range in a $39.6m offering, having previously raised some $117m in financing.
Life360 revolves to $105m IPO
ADT, BMW and Duchossois Group have achieved exits after people-tracking app developer Life360 became one of the few US-based companies to float in Australia.
Axcella accepts public listing
Metabolic therapy developer Axcella Health has priced its shares at $20 each in an offering that enabled Nestlé Health Science to exit.
NextCure executes $75m in initial public offering
The immunotherapy developer, which counts Eli Lilly, Pfizer, Taiho and Ping An as investors, floated in the middle of its range after raising $160m in venture funding.
Trevi tracks $55m in IPO
Lundbeck-backed pruritus therapy developer Trevi Therapeutics raised $55m when it floated, but had to price its shares significantly below its range.
Uber arrives on public markets with $8.1bn
SoftBank Vision Fund is selling $245m of shares while PayPal is investing $500m in the ride hailing service, in the world's largest IPO since 2014.

Editor's Picks

Uber arrives on public markets with $8.1bn
SoftBank Vision Fund is selling $245m of shares while PayPal is investing $500m in the ride hailing service, in the world's largest IPO since 2014.
Pinterest hits NYSE in $1.4bn IPO
Qualcomm-backed visual social media platform Pinterest floated above its range in an offering that will give it a market cap near $13bn.
Zoom crashes into public markets with $751m
Zoom is floating above its range in an IPO in which Qualcomm will make an immediate $30.6m return, while Salesforce is buying $100m of shares through a private placement.
IPO of the Year: DocuSign
A leading company in the e-signature and digital transaction management space, San Francisco-based DocuSign went public in April last year, with a market capitalization of $4.4bn.
test reg